Remplir Approved to Commence Sales in US$84M Thai Market
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This approval follows an expedited registration process and positions Orthocell to expand its presence in Asia, having already secured approvals in multiple other regions. The company plans to partner with a local distributor in Thailand and anticipates first sales in the latter half of the year. Orthocell is well-funded with significant cash reserves to support its global rollout of products.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Orthocell
- First US Distributors Signed for Remplirs US$1.6B market
- Regulatory Approval for Striate in US$65M Brazilian Market
- Remplir Cleared to Commence Sales in US$1.6B US Market
- Investor Presentation - US FDA 510(k) Clearance for Remplir
- First Sales of Striate in Germany, Austria & Swiss Region
Later from Orthocell
- Pause in Trading
- Replacement Trading Halt
- Remplir Approved to Commence Sales in US$75m Canadian Market
- 12 Distributors Signed for Remplir Covering 21 States in US
- Remplir Approved to Commence Sales in the Hong Kong Market
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell